You are here

A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

Last updated on August 1, 2019

FOR MORE INFORMATION
Study Location
University of Alabama at Birmingham
Birmingham, Alabama, 35233 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Breast Cancer
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Women 18 years of age or older, who are either: Postmenopausal or Pre/perimenopausal
women with medically-induced menopause by treatment with agents to induce chemical
menopause.

- Histologically or cytologically proven diagnosis of breast cancer with evidence of
metastasis.

- Documentation of estrogen receptor positive ((ER+), human epidermal growth factor
receptor 2 (HER2 negative (HER2-)) tumor.

- Dose Escalation Portion: Patients must satisfy one of the following criteria:

- Letrozole combination cohort (L): metastatic breast cancer (MBC) with progression
who are candidates for a letrozole-containing regimen, with palbociclib.

- Fulvestrant combination cohort (F): MBC with progression who are candidates for a
fulvestrant containing regimen, with palbociclib.

- Dose Expansion Portion: Patients must satisfy one of the following criteria:

- Arm A: MBC with progression and no prior endocrine based systemic therapy in the
metastatic setting;

- Arm B: MBC with progression during or following one prior endocrine based
systemic therapy in the metastatic setting, with no prior therapy with any
cyclin-dependent kinase (CDK) inhibitor;

- Arm C/Arm D: MBC with progression during or following one or two prior endocrine
based systemic therapies in the metastatic setting, and following prior therapy
with a CDK inhibitor.

- Measurable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST)
version 1.1.

- Bone only patients during dose escalation portion.

- Availability of archival tumor biopsy sample or willing to provide fresh biopsy if not
available.

- Eastern Cooperative Oncology Group [ECOG] performance must be 0 or 1.

- Adequate bone marrow, renal and liver function.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Prior treatment with a mechanistic target of rapamycin (mTOR) inhibitor or
phosphoinositide 3-kinase (PI3K) inhibitor.

- More than 1 line of prior chemotherapy in the treatment of metastatic or locally
advanced/recurrent disease.

- Bone only patients during expansion/efficacy portion.

- Patients with advanced/metastatic disease who have symptomatic visceral spread, and
who have life threatening complications needing immediate therapy, such as massive
uncontrolled effusions [pleural, pericardial, peritoneal], pulmonary lymphangitis, and
over 50% liver replacement with tumor.

- Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases.

- Active bacterial, fungal or viral infection.

- Uncontrolled or significant cardiovascular disease.

- Radiation therapy within 4 weeks of investigational product.

- Cytotoxic chemotherapy within 4 weeks of investigational product (6 weeks for
mitomycin C or nitrosoureas) if immediate prior regimen was administered on an every 3
4 week schedule or 2 weeks of investigational product if immediate prior regimen
consisted of weekly therapy.

- Any other anti cancer agents (eg, hormonal, biological, investigational) within 5
times the half life prior to investigational product.

- Impairment of gastro intestinal (GI) function or GI disease.

- Pregnant female patients; breastfeeding female patients; and female patients of
childbearing potential who are unwilling or unable to use 2 highly effective methods
of contraception as outlined in this protocol for the duration of the study and for 90
days.

NCT02684032
Pfizer
Recruiting
A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Non-Small Cell Lung Cancer, Triple-negative Breast Cancer
NCT03674827
All Genders
18+
Years
Multiple Sites
Advanced Breast Cancer, Metastatic Breast Cancer
NCT03280303
All Genders
18+
Years
Multiple Sites
Ovarian Cancer HR+ HER2- Metastatic Breast Cancer
NCT03519178
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now